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interference RNAParcs/Gpn3 is a putative GTPase that is conserved in eukaryotic cells from yeast to humans, suggesting that it
plays a fundamental, but still unknown, cellular function. Suppression of Parcs/Gpn3 expression by RNAi
completely blocked cell proliferation inMCF-12A cells and other mammary epithelial cell lines. Unexpectedly,
Parcs/Gpn3 knockdown had a more modest effect in the proliferation of the tumorigenic MDA-MB-231 and
SK-BR3 cells. RNA polymerase II (RNAP II) co-immunoprecipitated with Parcs/Gpn3. Parcs/Gpn3 depletion
caused a reduction in overall RNA synthesis in MCF-12A cells but not in MDA-MB-231 cells, demonstrating a
role for Parcs/Gpn3 in transcription, and pointing to a defect in RNA synthesis by RNAP II as the possible cause
of halted proliferation. The absence of Parcs/Gpn3 in MCF-12A cells caused a dramatic change in the sub-
cellular localization of Rpb1, the largest subunit of RNAP II. As expected, Rpb1 was present only in the nucleus
of MCF-12A control cells, whereas in Parcs/Gpn3-depleted MCF-12A cells, Rpb1 was detected exclusively in
the cytoplasm. This effect was speciﬁc, as histones remained nuclear independently of Parcs/Gpn3. Rpb1
protein levels were markedly increased in Parcs/Gpn3-depleted MCF-12A cells. Interestingly, Rpb1
distribution was only marginally affected after knocking-down Parcs/Gpn3 in MDA-MB-231 cells. In
conclusion, we report here, for the ﬁrst time, that Parcs/Gpn3 plays a critical role in the nuclear accumulation
of RNAP II, and we propose that this function explains the relative importance of Parcs/Gpn3 in cell
proliferation. Intriguingly, at least some tumorigenic mammary cells have evolved mechanisms that allow
them to proliferate in a Parcs/Gpn3-independent manner.rsidad Autónoma de San Luis
, San Luis Potosí, SLP, México.
ez-Olea).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
In a previous study we identiﬁed a novel protein we named Parcs,
for pro-apoptotic protein required for cell survival, by its ability to
interact with the oligomerization domain of Apaf-1 [1]. This 33-kDa
protein belongs to the Gpn family of GTPases, whose name derives
from the presence of a strictly conserved GPN (glycine, proline and
asparagine residues) structural motif [2]. The Gpn protein family
comprises only three members: Gpn1 (XAB1/MBDin/RPAP4), Gpn2,
and Gpn3 (Parcs) [1,3]. Gpn proteins display a high degree of
sequence similarity with each other, and all three proteins contain a
guanine nucleotide-binding domain. Parcs is highly conserved from
yeast tomammals, suggesting that it may serve a fundamental cellular
function. In this regard, its ortholog in Saccharomyces cerevisiae is
classiﬁed as an essential gene [4]. In addition, inactivation of the Parcs
ortholog in C. elegans by interference RNA results in embryonic
lethality [5–7].Parcs/Gpn3 has been reported to participate in the regulation of
RNA polymerase II in yeast [8]. RNA polymerase II (RNAP II) is the core
component of the complex apparatus responsible of synthesizing all
mRNAs in eukaryotic organisms. RNAP II is a large, multi-subunit
enzyme, of about 0.5MDa, which in order to recognize a promoter and
initiate RNA synthesis requires additional proteins termed general
transcription factors: TFIIA, TFIIB, TFIID, TFIIF, and TFIIH [9–13]. The
RNAP II core is composed of at least 12 different proteins encoded by
the RPB1 to RPB12 genes, which share extensive conservation among
eukaryotic organisms [14–16]. Rpb1, the largest subunit of RNAP II,
contains numerous repeats in tandem of a heptapeptide sequence at
its carboxy-terminal domain (CTD) [17]. The number of repeats
increases with the complexity of the organisms, being 26 and 52
repeats in yeast and human, respectively [18,19]. Phosphorylation of
Rpb1 at serine residues on the position 2 and 5 of this heptapeptide is
part of a conserved regulatory mechanism of eukaryotic RNA
polymerase II function.
Parcs/Gpn3 was shown to be a critical protein for cell proliferation
in MCF-10A but not in HeLa cells [1]. These two cell lines differ in two
aspects: tissue of origin and their tumorigenic nature. MCF-10A cells
were derived from breast tissue and are considered very close to
normal cells and are, therefore, incapable of forming tumors. HeLa
cells, on the other hand, were derived from the cervix and are highly
1709M.R. Calera et al. / Biochimica et Biophysica Acta 1813 (2011) 1708–1716tumorigenic. In this study, we investigated the relative importance of
Parcs on the proliferation of several cell lines derived from a common
origin, the human breast. There is a collection of human breast
epithelial cell lines distributed worldwide by ATCC, whose tumori-
genic properties have been thoroughly characterized. Based on a
previous report documenting that a conditional suppression of the
Parcs ortholog in yeast affected the global gene expression pattern in
basically the same manner as the inhibition of two different subunits
of the RNA polymerase II [8], we investigated, in Parcs-dependent cell
lines, the possibility that this multi-subunit enzymatic complex
involved in the synthesis of all messenger RNAs is a critical molecular
target of Parcs. We demonstrate here that RNAP II co-immunopre-
cipitates with Parcs/Gpn3. Silencing of Parcs/Gpn3 caused a signiﬁ-
cantly decrease in cell transcription and a dramatic relocalization of
RNP II from the cell nucleus to the cytoplasm. This cytoplasmic Rpb1 is
in a hypophosphorylated state, but the total Rpb1 protein levels were
signiﬁcantly increased in the absence of Parcs/Gpn3. Finally, we show
that the tumorigenic MDA-MB-231 cells somehow become Parcs
independent in all parameters examined: RNAP II is in the cell
nucleus, they display normal transcriptional activity and proliferate in
the absence of Parcs/Gpn3.
2. Material and methods
2.1. Antibodies and reagents
Anti-mouse and anti-rabbit immunoglobulins G conjugated to
horseradish peroxidase (HRP), and mouse monoclonal anti-tubulin
antibody were obtained from Sigma (St. Louis, MO). Anti-goat
immunoglobulin G conjugated to HRP, goat polyclonal anti-Apaf-1
and goat polyclonal anti-Rpb2 antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The rabbit polyclonal antibody
against Parcs was used as described previously [1]. Mousemonoclonal
anti-pan-histone antibody was obtained from Chemicon (Temecula,
CA). Rabbit polyclonal anti-phospho-Rpb1 antibodies against Ser-2
and Ser-5 were purchased from Abcam (Cambridge, MA). Mouse
monoclonal anti-Rpb1 antibody for total protein (8WG16) was from
Covance (Emerville, CA). Chemicals and reagents were obtained from
Sigma and, unless otherwise indicated, all tissue culture reagents
were from Invitrogen (Carlsbad, CA).
2.2. Cell culture conditions
All human mammary epithelial cells and HEK 293 T/17 cells were
obtained from American Type Culture Collection (Manassas, VA). BT-
474, MDA-MB-231, MDA-MB-468, SK-BR3 and HEK 293 T/17 cells
were grown and maintained in high-glucose Dulbecco´s modiﬁed
Eagle´s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). MCF-12A was cultured in DMEM-F12 with 5% horse serum,
20 ng/ml EGF, 100 ng/ml cholera toxin, 10 μg/ml insulin and 0.5 μg/ml
hydrocortisone [20,21]. All culture medium contained 100 U/ml
penicillin and 100 μg/ml streptomycin in a humidiﬁed air-CO2
atmosphere at 37 °C.
2.3. shRNA-mediated depletion of Parcs/Gpn3
To stably suppress Parcs expression, we employed pSRP, a self-
inactivating retroviral vector, to direct the expression of speciﬁc short-
hairpin RNAs to suppress Parcs expression. The oligonucleotide
sequences of these shRNAs were as follows: g193, GAGGAT-
GATTCTCTGCGAT; g325, GGTCAGATTGAGTTGTACA; and control g239,
GCATGGAGTACTTTGCCAA. To suppress Apaf-1 expression we used the
sequence we called g2127: GTGACTGCTTCCTCAAACT. Retroviruses
were produced as previously described [1]. In brief, retroviruses were
produced in HEK 293 T/17 cells with the corresponding plasmid
together with gag-pol- and vsv-g-expressing plasmids. Cells weretransfected by the calcium phosphate method and retroviral particles
were collected 48 h after transfection. To infect human mammary
epithelial cells, the retroviral particles were diluted 1:2 with fresh
culture medium and added to the monolayer of cells in the presence of
8 μg/ml polybrene. After removing the viral medium, cells were grown
in the presence of puromycin (1.25 ug/ml to 6 μg/ml, depending on the
cell line) to select the resistant population of cells.
2.4. Cell proliferation
Puromycin-resistant human mammary epithelial cells expressing
the indicated Parcs shRNA were trypsinized and counted four days
after infection and equal number of cells was plated per well in 6-well
plates. Cell proliferation was determined by counting the number of
cells four days later. Data point represents the mean±SD of at least
four independent experiments.
2.5. Assessment of RNA synthesis
To assess RNA synthesis we employed the method of 5-
ethynyluridine labeling described by Jao and Salic [22]. MDA-MB-
468 cells were grown on glass coverslips in complete cell culture
medium. 1 mM 5-ethynyluridine (EU, Invitrogen) was added for 1 h
at 37 °C. MCF-12A and MDA-MB-231 cells were grown in tissue
culture plastic dishes. After EU labeling, cells were washed with
phosphate buffered saline solution (PBS) and ﬁxed in 125 mM Pipes
(pH 6.8), 1 mM MgCl2, 10 mM EGTA, 0.2% Triton X-100, with 3.7%
formaldehyde for 30 min at 25 °C. Fixed cells were rinsed twice with
TBS (Tris buffered saline), and stained with a ﬂuorescent azide
(Invitrogen).
2.6. Protein extraction
Cells were washed with ice-cold PBS and then scraped into lysis
buffer consisting of 50 mM Tris (pH 7.4), 1% Triton X-100, 150 mM
NaCl, 1 mM MgCl2, 1 mM EDTA, 1 mM DTT and 1 mM PMSF. After
incubating cells for 20 min on ice, the lysates were cleared by
centrifugation at 13,000 rpm (Sorvall Model 21R) for 10 min at 4 °C.
Finally, 2XSDS-containing Laemmli buffer was added to the soluble
fraction and proteins were analyzed by immunoblotting (see below).
2.7. Western blot analysis
Samples were separated on SDS- 8 or 10% polyacrylamide gels
[23], and then electrophoretically transferred to polyvinylidene
diﬂuoride membranes (0.45 μm, Millipore, Billerica, MA) at 25 °C for
30 min. The membranes were incubated in PBST containing 5% non-
fat dry milk for 1 h at 25 °C to block nonspeciﬁc binding, then probed
with the indicated speciﬁc antibody. To detect the antigen-bound
antibody, the blots were treated with the corresponding secondary
antibody conjugated with horseradish peroxidase. Immunoreactivity
was detected using the enhanced chemiluminescence system.
Immunoblots were quantiﬁed by densitometry analysis using the
Molecular Imager and Quantity One software (Bio-Rad, Hercules, CA).
2.8. Parcs/Gpn3 immunoprecipitation
Adherent cells were washed twice with ice-cold PBS and scraped
into 1 ml of lysis buffer (50 mM Tris-base [pH 8.0], 150 mM NaCl, 1%
Triton X-100, 1 mM PMSF). Cell lysates were incubated for 20 min on
ice and then cleared by centrifugation at 13,000 rpm for 10 min at
4 °C. The soluble fractions were then incubated with a rabbit
polyclonal antibody speciﬁc for Parcs for 2 h, after which 40 μl of
protein A covalently bound to sepharose (Santa Cruz Biotechnology)
was added. After rotation for 2 h at 40 C, immunocomplexed beads
were washed brieﬂy ﬁve times with lysis buffer. Beads were heated at
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tants were kept frozen at −20 °C until processed for Western blot
analysis as described above.Parcs/Gpn3
Tubulin
Fig. 1. Parcs/Gpn3 is expressed in human mammary epithelial cells. Human breast
epithelial cells of the indicated cell line were harvested, and total cellular proteins were
separated by SDS/PAGE, transferred to PVDF membranes, and immunoblotted with an
antibody speciﬁc for Parcs/Gpn3 (upper panel) or tubulin (lower panel).2.9. Immunoﬂuorescence
Control or Parcs/Gpn3-depleted MCF-12A or MDA-MB-231 cells
were washed twice with PBS and ﬁxed with 4% formaldehyde in PBS
(pH 7.4) for 15 min at room temperature. After rinsing the cells with
PBS, cells were permeabilized and blocked in one step by incubating
them in PBS containing 0.2% Triton X-100 and 10% fetal bovine serum
for 15 min at room temperature. Cells were then incubated overnight
with either Rpb1 or histones antibody at 4 °C. The Rpb1 mouse
monoclonal antibody 8GW16 from Covance was used at a dilution
1:100. The antibody for histones is a pan monoclonal antibody able to
detect the histones H1, H2A, H2B, H3 and H4 with equal sensitivity,
and it was acquired from Chemicon. After removing the primary
antibody, the cells were incubated for three periods of 3 min each in
PBS, followed by a 30 min-incubation with Alexa Fluor 568-conjugat-
ed anti-mouse secondary antibody acquired from Molecular Probes.
Finally, the cells were counterstained with DAPI to visualize nuclei.
Images were collected with an Olympus inverted microscope
equipped with an evolution MP camera.3. Results
In the initial study describing Parcs/Gpn3, it was reported that
whereas the proliferation of MCF-10A cells was completely blocked by
suppressing Parcs/Gpn3 expression, HeLa cells could divide normally
in the absence of this protein [1]. This ﬁnding was really surprising, as
Parcs/Gpn3 is an essential protein in yeast and C. elegans (see
Introduction). AlthoughMCF-10A and HeLa cells are both of epithelial
origin, there is a salient feature that distinguishes them:whereas HeLa
cells possess the ability to form tumors, MCF-10A cells lack this
property. Thus, it is temping to link this difference with the relative
importance of Parcs/Gpn3 in cell proliferation. However, these cell
lines were derived from different tissues. Here, we directly investi-
gated the proposal that tumorigenic cells differ from the non-
tumorigenic ones in their dependence on Parcs/Gpn3 to proliferate.
To this end we determined the effect of suppressing Parcs/Gpn3
expression using interference RNA on the proliferative capacity of
several human breast epithelial cell lines previously characterized on
their tumorigenic capacity.3.1. Expression of Parcs/Gpn3 in human breast epithelial cell lines
We ﬁrst investigated if Parcs/Gpn3 was expressed in the human
breast cell lines examined in this study. Cell extracts were prepared
from an equal number of cells per unit of volume, and proteins were
separated in SDS-PAGE gels, transferred to PVDF membranes, and
probed with a rabbit polyclonal antibody speciﬁc for Parcs/Gpn3. The
results in Fig. 1 (upper panel) demonstrated that Parcs/Gpn3 is
present in all human mammary epithelial cell lines examined. The
highest Parcs/Gpn3 protein levels are detected in BT-474 and MCF-
12A cell lines but Parcs/Gpn3 was also expressed in MDA-MB-231,
MDA-MB-468 and SK-BR3 cells.Fig. 2. Parcs/Gpn3 is essential for cell proliferation in some, but not all, human breast epithe
the non-effective, control Parcs/Gpn3 shRNA g239 or the highly effective shRNAs to dow
retroviral particles into 6-well tissue culture plates and grown for four more days before cou
adjusted for the different cell lines in order to have sub-conﬂuent cultures during the
experiments). Parcs/Gpn3 and tubulin protein levels at the beginning of the proliferation
examined are: A) MCF-12A, B) MDA-MB-231, C) SK-BR3, D) BT-474, E) MDA-MB-468. In A
shRNA effective to knockdown Apaf-1. The ratio for Parcs/Gpn3 protein levels between shRN
it was calculated after normalizing for protein loading using tubulin. For Apaf-1 the ratio b3.2. Effect of silencing Parcs/Gpn3 expression by speciﬁc shRNAs on cell
proliferation
To determine the effect of suppressing Parcs/Gpn3 expression in
human mammary epithelial cells on cell proliferation, we ﬁrst
determined the conditions required to effectively decrease Parcs/
Gpn3 protein levels by interference RNA. We employed the retroviral
vector pSRP to express Parcs/Gpn3 shRNAs. The packaging of the
retroviral particles was carried out in HEK 293 T/17 cells as described
in Material and methods. In our initial studies, the Parcs/Gpn3 shRNA
g239was completely ineffective to decrease Parcs/Gpn3 protein levels
and we used that construct as a control in all our experiments.
Parcs/Gpn3 has previously been demonstrated to be an essential
protein for proliferation in normal cells, including primary mouse
embryonic ﬁbroblasts and MCF-10A cells [1]. Here, we examined ﬁrst
the effect of suppressing Parcs/Gpn3 expression in MCF-12A cells,
another non-tumorigenic cell line very close to normal mammary
cells. Parcs/Gpn3 protein levels were almost undetectable in MCF-12A
infected with the retrovirus encoding an shRNA (g193) designed to
selectively silence Parcs/Gpn3 expression (Fig. 2A, lower panel).
Tubulin protein levels were very similar in extracts from cells infected
with the retroviral constructs expressing Parcs/Gpn3 shRNAs g239 or
g193, conﬁrming that a similar amount of total protein had been
loaded in the gels. To assess the effect of Parcs/Gpn3 knockdown on
the proliferative capacity of MCF-12A cells, 5×104 control or Parcs/
Gpn3-depleted cells were seeded per well, and cells were detached
with trypsin and counted in a Neubauer chamber four days later. MCF-
12A cells expressing an empty pSRP retroviral vector, an effective
shRNA for Apaf-1, or the ineffective Parcs shRNA g239, increased in
number from 5×104 to around 95×104. However, cell proliferation
was completely inhibited in MCF-12A cells expressing the highly
effective Parcs/Gpn3 shRNA g193 (Fig. 2A, upper panel). In fact, Parcs/
Gpn3 knockdown caused a decrease in cell number from 5 to 2.3×104
in the same period. This result demonstrates that MCF-12A cells
depend completely on the presence of Parcs to proliferate.
Next we investigated the importance of Parcs/Gpn3 in the
proliferation of other breast-derived epithelial cell lines. We began
our analysis with the tumorigenic cell line MDA-MB-231. Parcs/Gpn3
is expressed in MDA-MB-231 cells and its protein levels were
successfully reduced by the Parcs/Gpn3 shRNA g193, and by a second
Parcs/Gpn3 shRNA (g325) targeting a different region of Parcs/Gpn3
mRNA (Fig. 2B, lower panel). To assess the proliferative capacity of
MDA-MB-231 cells, 20×104 cells were seeded per well in 6-welllial cells. An equal number of cells expressing the indicated Parcs/Gpn3 shRNAs (either
nregulate Parcs/Gpn3, g193 or g325) were seeded four days after infection with the
nting the total number of cells (A to E). The initial number of cells plated per well was
whole evaluation period. Results are the average±S.D. (n=at least 3 independent
experiment are shown at the bottom of each panel. Human epithelial breast cell lines
(MCF-12A cells) we include two more shRNAs as controls, pSRP empty vector and an
A g193 or shRNA g325 and shRNA g239 is indicated below the corresponding panels and
etween g2127 and the empty pSRP vector is shown.
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Fig. 3. RNA polymerase II co-immunoprecipitates with Parcs/Gpn3. MDA-MB-468
human mammary epithelial cells were lysed, and soluble cell extracts subjected to
immunoprecipitation with a Parcs/Gpn3 speciﬁc rabbit polyclonal antibody. Proteins in
the immunoprecipitate were separated by SDS-PAGE and transferred to a PVDF
membrane. Western blot analysis was performed with anti-Rpb1 (upper panel) or
Rpb2 (lower panel) antibodies as described in Material and methods.
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Gpn3 shRNA g239 increased in number from 20 to 103.8×104 cells.
Interestingly, MDA-MB-231 cells expressing the Parcs/Gpn3 shRNAs
g193 or g325 increased from 20 to 80.2 and 58.9×104, respectively
(Fig. 2B). Thus, both Parcs/Gpn3 shRNAs caused a rather moderate
decrease in cell proliferation. We then extended our analysis to the
tumorigenic SK-BR3 cell line. Parcs/Gpn3 shRNAs, g193 and g325,
were highly effective to suppress Parcs/Gpn3 expression, as Parcs/
Gpn3 protein levels were almost undetectable (Fig. 2C, lower panel).
SK-BR3 cells expressing the Parcs/Gpn3 shRNA control g239 increased
from 20 to 69.9×104 cells during the proliferation assay. SK-BR3 cells
expressing the highly effective Parcs/Gpn3 shRNAs g193 or g325
increased from 20 to 47.6 or 48.8×104 cells, respectively (Fig. 2C).
Thus, the importance of Parcs/Gpn3 in cell proliferation was
signiﬁcantly different in the tumorigenic cells MDA-MB-231 or SK-
BR3 and the non-tumorigenic MCF-12A cells. We then, extended our
analysis to two more tumorigenic human breast cancer cell lines: BT-
474 and MDA-MB-468 cells. Cell proliferation was completely
inhibited in the absence of Parcs/Gpn3 in both tumorigenic cell
lines, BT-474 (Fig. 2D) and MDA-MB-468 (Fig. 2E). Both Parcs/Gpn3
shRNAs, g193 and g325, were able to successfully decrease Parcs/
Gpn3 protein levels in BT-474 cells (Fig. 2D, lower panel). Control
(Parcs/Gpn3 shRNA g239) BT-474 cells increased from 20 to
57.7×104 during the proliferation test period but cells expressing
the Parcs/Gpn3 shRNA g193 o g325 did not proliferate at all, as the
initial value of 20 actually decreased to 12.55 or 18.25×104,
respectively (Fig. 2D). We obtained similar results with MDA-MB-
468 cells. Parcs/Gpn3 protein levels were dramatically reduced in
MDA-MB-468 cells expressing the Parcs/Gpn3 shRNA g193 (Fig. 2E,
lower panel). MDA-MB-468 cells expressing the ineffective Parcs/
Gpn3 shRNA control g239, increased from 15 to 45.2×104, whereas
cells expressing the Parcs/Gpn3 shRNA g193 in fact decreased from 15
to 10.3×104. These results demonstrate that although Parcs/Gpn3
expression was successfully suppressed in all the tumorigenic human
mammary epithelial cell lines examined, some cells still proliferate in
its absence. Perhaps, these cells have developed alternative mecha-
nisms to proliferate.
3.3. RNA polymerase II co-immunoprecipitates with Parcs/Gpn3
As mentioned above, Parcs/Gpn3 belongs to the Gpn protein
family. Gpn1, another member of this family, was recently identiﬁed
by mass spectrometry as a protein that associates with RNA
polymerase II (RNAP II) [8], and given the name of RPAP4. Based onthis ﬁnding, we explored the possibility that Parcs/Gpn3 could also
associate with RNAP II. Parcs/Gpn3 was immunoprecipitated from
soluble cell extracts with a rabbit polyclonal antibody. Proteins in this
immunoprecipitate were separated by SDS-PAGE, transferred to PVDF
membrane and blotted with an antibody speciﬁc for Rpb1. The signal
corresponding to Rpb1 was clearly present in the Parcs immunopre-
cipitate (Fig. 3), demonstrating that these proteins are indeed part of a
single protein complex. Next, we examined if other subunits of RNAP
II were also present in the Parcs immunoprecipitate. Rpb2, the second
largest subunit of RNAP II, was also present in this material (Fig. 3).
The association of Rpb1 and Rpb2 with Parcs was speciﬁc, as they
were not detected in the control immunoprecipitate (Fig. 3). These
results clearly demonstrate that Parcs has the ability to physically
associate with RNAP II.
3.4. Silencing of Parcs/Gpn3 decreased transcriptional activity in cell
lines whose proliferation was Parcs-dependent but not in those that
proliferate independently of Parcs/Gpn3
A previous report demonstrated that silencing the gene encoding
the yeast ortholog of Parcs/Gpn3, YLR243W, in a yeast strain with
conditional promoters, affected gene expression in an identical
manner to suppressing two different proteins associated with RNA
polymerase II [8]. As Parcs/Gpn3 is a highly conserved protein during
evolution, we hypothesized that its function in mammalian cells must
be very similar to the one observed in yeast. Next, we investigated if
the silencing of Parcs/Gpn3 resulted in an overall inhibition in
transcription in mammalian cells. MDA-MB-468 cells were infected
with retroviral particles encoding Parcs/Gpn3 shRNA g239 or g193,
selected with puromycin and plated on glass coverslips. To qualita-
tively assess RNA synthesis, we employed a recently described
method that relies in the incorporation of the uridine analog 5-
ethynyluridine (see Material and methods) into RNA transcripts,
followed by the covalent labeling of the incorporated EU with a
ﬂuorofore [22]. We found that MDA-MB-468 cells infected with the
Parcs/Gpn3 shRNA control g239 display a very strong signal,
indicating a high transcriptional activity (Fig. 4A). This signal was
clearly diminished in MDA-MB-468 cells expressing the Parcs/Gpn3
shRNA g193 (Fig. 4A). These results demonstrated for the ﬁrst time
that mammalian cells deﬁcient in Parcs/Gpn3 expression had an
important deﬁciency in transcriptional activity, and we propose that
this decrease in transcriptional activity is causally linked to the
inhibition in cell proliferation we described above. To test this
proposal, we assessed the effect of depleting Parcs/Gpn3 on the
transcriptional activity of other two cell lines, MCF-12A andMDA-MB-
231 cells, whose proliferation is dependent and independent of Parcs/
Gpn3, respectively. The transcriptional activity of MCF-12A (Fig. 4C),
but not MDA-MB-231 (Fig. 4E), was markedly reduced by Parcs/Gpn3
depletion. These results conﬁrm that Parcs/Gpn3 is required for an
optimal transcriptional activity in those cells that proliferate in a
Parcs/Gpn3-dependent manner, but not in those cells that proliferate
independently of Parcs/Gpn3. In any case, it is clear that themolecular
mechanism controlled by Parcs/Gpn3 in the cell is at the level of
transcription, very likely, by RNAP II (see below).
RNAP II can exist in several forms based on the phosphorylation
state of Rpb1, the largest subunit of the enzyme. One form is
nominated IIA, and corresponds to the transcription initiating form of
the enzyme that contains a non-phosphorylated carboxy-terminal
domain (CTD), an unusually long extension appended to the carboxy-
terminus of Rpb1. The other form is called II0, which is the fraction of
the enzyme engaged in transcription elongation, and contains a highly
phosphorylated CTD. This phosphorylation occurs principally on Ser2
and Ser5 [24,25] of the repeated heptapeptide. The phosphorylation
status of Rpb1 is an event that is often used as a marker to distinguish
speciﬁc phases of the polymerase II cycle of activity. While
phosphorylation on Ser2 is a late event during transcription
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Day 4 Day 6
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D
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Fig. 4. The suppression of Parcs expression by RNAi caused a global decrease in transcriptional activity. RNA synthesis was assessed as described inMaterials andmethods. A decrease
in the ﬂuorescence signal corresponds to a reduction in transcriptional activity. shRNA g239 corresponds to the control condition, and the shRNA g193 indicates the Parcs/Gpn3
knockdown cells. A) RNA synthesis in MDA-MB-468. B) Western blot analysis of MDA-MB-468 total cell extracts from panel A with the antibodies for the proteins indicated on the
left side of the panels. The ratio of PSer5 Rpb1/Rpb1 is indicated below the top panel. C) RNA synthesis in MCF-12A cells. D)Western blot analysis of MCF-12A total cell extracts from
panel C with the antibodies for the proteins indicated on the left side of the panels. The ratio of PSer2 Rpb1/Rpb1 is indicated below the top panel. E) RNA synthesis in MDA-MB-231
cells. Parcs/Gpn1 protein levels are also indicated.
1713M.R. Calera et al. / Biochimica et Biophysica Acta 1813 (2011) 1708–1716elongation, phosphorylation on Ser5 of the CTD occurs early in the
transcriptional cycle and is linked to RNA polymerase II release from
the promoter. As a ﬁrst approximation to investigate the regulatory
mechanism of RNA polymerase II by Parcs/Gpn3, we evaluated the
effect of suppressing Parcs/Gpn3 expression on the phosphorylation
state of Rpb1-CTD on Ser5. Total cell lysates of MDA-MB-468 cells
expressing the Parcs/Gpn3 shRNA control g239 or g193 were
prepared, proteins were separated in SDS-PAGE, transferred to PVDF
membrane and probed with a speciﬁc antibody for phospho-Ser5 on
the CTD. Analysis by western blot demonstrated that the signal
corresponding to phospho-Ser5 Rpb1 was very robust in control cells
(Fig. 4B) and that this signal was markedly reduced in cells with
suppressed Parcs/Gpn3 expression (Fig. 4B). The decrease in
phospho-Ser5 is not caused by a reduction in total Rpb1 total protein
levels. Interestingly, cells lacking Parcs/Gpn3 showed a tendency to
increase the total Rpb1 protein levels (Fig. 4B, middle panel), probablyas a compensatory mechanism to sustain the transcriptional needs of
the cell. A clear reduction in the phosphorylation of Ser2 in the Rpb1
CTD was observed after depleting Parcs/Gpn3 in MCF-12A cells
(Fig. 4D). The absence of Parcs/Gpn3 resulted in an even more
pronounced increase in Rpb1 protein levels inMCF-12A cells (Fig. 4D).
Altogether, these results demonstrate that Parcs/Gpn3 is a critical
regulator of the transcriptional activity of RNAP II.
3.5. Parcs/Gpn3 is required for the nuclear localization of RNA
polymerase II
It is extremely surprising that there is abundant functional and
structural information on RNAP II, but absolutely nothing is known on
the mechanism that allows the enzyme to enter the cell nucleus. It is
clear that none of the 12 constitutive subunits of RNAP II contains a
classical, or otherwise recognizable nuclear localization signal.
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Fig. 5. Parcs/Gpn3 depletion causes an inhibition in the nuclear localization of RNAP II. Parcs/Gpn3 was depleted and the sub-cellular localization of the Rpb1 subunit of RNAP II was
examined by immunoﬂuorescence. In A and C, the left column corresponds to the Rpb1 signal, the middle column to the nuclear marker DAPI, and the right column to a merge of
these two signals. In B, the left column corresponds to the histones, the middle column to the nuclear marker DAPI, and the right column to a merge of these two signals. A) Sub-
cellular localization of Rpb1 in control (shRNA g239, upper panel) or Parcs/Gpn3 knockdown (shRNA g193, lower panel) MCF-12A cells. B) Sub-cellular localization of histones. The
antibody used can detect all ﬁve histones, H1, H2A, H2B, H3 and H4, in control (shRNA g239, upper panel) or Parcs/Gpn3 knockdown (shRNA g193, lower panel) MCF-12A cells. C)
Sub-cellular localization of Rpb1 in control (shRNA g239, upper panel) or Parcs/Gpn3 knockdown (shRNA g193, lower panel) MDA-MB-231 cells.
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DNA substrate is located. While our work was in revision, the ﬁrst
protein needed for the nuclear accumulation of RNAP II [26] wasdescribed and termed RPAP4. Surprisingly, this protein turned out to
be Gpn1, a protein that belongs to the same protein family as
Parcs/Gpn3. There is a high degree of similarity at the amino acid
1715M.R. Calera et al. / Biochimica et Biophysica Acta 1813 (2011) 1708–1716sequence level and it is likely that they could both play the same
function. An involvement of Parcs/Gpn3 in the nuclear accumulation
of RNAP II could explain all our ﬁndings: a physical association of
Parcs/Gpn3 with RNAP II, a clear inhibition in transcriptional activity
after Parcs/Gpn3 depletion, as well as a reduction in the phosphor-
ylation state of the Rpb1 subunit of RNAP II. Next, we performed
experiments to examine the possibility that Parcs/Gpn3 could func-
tion in a similar manner to Gpn1/RPAP4 and that it would be,
therefore, involved in the nuclear localization of RNAP II. Thus, we
analyzed the effect of Parcs/Gpn3 depletion on the cellular localiza-
tion of Rpb1. For these studies we employed two cells lines: MCF-12A
cells, which depend entirely on Parcs/Gpn3 to proliferate, and MDA-
MB-231 cells, which proliferate independently of Parcs. As expected,
in both control MCF-12A and MDA-MB-231 cells, Rpb1 was detected
exclusively in the cell nucleus (Fig. 5A and 5C, respectively). However,
Rpb1 distribution was very different in these two cell lines in the
absence of Parcs. While in the this condition, Rpb1 could still be
detected only in the nucleus of MDA-MB-231 cells, in the MCF-12A
cells Parcs-depletion caused an impressive change in Rpb1 distribu-
tion, and Rpb1 was exclusively detected in the cytoplasm of the cells
(Fig. 5A). This relocation of Rpb1 was not the result of a non-speciﬁc
effect in the nuclear transport systems, or a general loss of nuclear
membrane selectivity, as histones were nuclear in control and Parcs/
Gpn3 knocked-down cells (Fig. 5B). This result points to a speciﬁc
effect of Parcs/Gpn3 depletion on the sub-cellular distribution of
RNAP II. These results can be summarized in two critical ﬁndings: ﬁrst
and most importantly, that Parcs/Gpn3 plays a critical role in the
nuclear accumulation of Rpb1 in mammalian cells, and second, that
the relative importance of Parcs/Gpn3 in cell proliferation is directly
related to the importance of this protein in the nuclear accumulation
of RNAP II. This result is also consistent with the sustained tran-
scriptional activity of Parcs/Gpn3 knockdownMDA-MB-231 cells (see
Fig. 4E). It will be of great interest to determine why Parcs/Gpn3 does
not participate in the nuclear accumulation of RNAP II in a few cell
lines, especially when, until now, all these cell lines have in common is
that they all are tumorigenic in nature.
4. Discussion
In this report we document that the recently isolated protein
Parcs/Gpn3 [1] is widely expressed in human breast epithelial cell
lines and provide experimental evidence that the suppression of
Parcs/Gpn3 expression by interference RNA leads to a complete
inhibition of cell proliferation in MCF-12A and other mammary
epithelial cell lines, including BT-474 and MDA-MB-468 cells.
Intriguingly, cell proliferation was more modestly affected by Parcs/
Gpn3 inhibition in MDA-MB-231 and SK-BR3 cells. To investigate the
molecular mechanisms regulated by Parcs/Gpn3, we ﬁrst demon-
strated that endogenous Parcs/Gpn3 is in the same protein complex as
RNAP II, and that the overall transcriptional activity is reduced in
Parcs/Gpn3 depleted cells. We succeeded in identifying the molecular
mechanism controlled by Parcs/Gpn3, as we demonstrated that in the
absence of Parcs/Gpn3, RNAP II fails to be nuclear and localizes
completely to the cytoplasm of the cell. In addition, Rpb1 protein
levels are markedly increased in cells with suppressed expression of
Parcs/Gpn3.
Although Parcs is an essential protein to sustain life in all
organisms examined (see introduction) there is little informational
cues on the molecular mechanisms regulated by this protein in the
cell. Since its original description [1], it was clear that Parcs/Gpn3 was
fundamental for cell proliferation in MCF-10A cells, although HeLa
cells proliferated normally in the absence of this protein. Proliferation
in the absence of Parcs may be a peculiarity of HeLa cells or it may be a
shared property with other cells. Here we explore the importance of
Parcs/Gpn3 in the proliferation of several human breast epithelial cell
lines, including the non-tumorigenic MCF-12A cells and the tumor-igenic cells lines BT-474, MDA-MB-231, MDA-MB-468 and SK-BR3
cells. MCF-12A cells and two of the tumorigenic cell lines, BT-474 and
MDA-MB-468, displayed a complete dependence on Parcs/Gpn3 to
proliferate, but cell proliferation of two tumorigenic cell lines, MDA-
MB-231 and SK-BR3, was much less affected by Parcs/Gpn3 depletion.
It is tempting to speculate that there could be a relationship between
the tumorigenic properties of the cells and their ability to proliferate
in the absence of Parcs/Gpn3, as all cell lines that proliferate without
Parcs/Gpn3 were tumorigenic cells: HeLa [1], MDA-MB-231 and SK-
BR3 (this work). It is likely that during the transformation process
leading to tumorigenesis, at least a subgroup of cells acquire changes
that endow them with mechanisms to cope or to compensate for the
absence of Parcs/Gpn3.Wewould not anticipate there would bemany
normal cell types with the capacity to proliferate in the absence of
Parcs/Gpn3. Inhibition of Parcs/Gpn3 in mouse embryonic ﬁbroblasts
isolated from a knock-out mouse engineered to conditionally
inactivate a ﬂoxed Parcs/Gpn3 allele with Cre recombinase, caused a
complete arrest in cell proliferation [1]. In addition, the constitutive
Parcs/Gpn3 knock-out mouse dies very early in development
(Sanchez-Olea, R. and J. Yuan, unpublished results), again supporting
the idea that Parcs/Gpn3 plays an essential role in the cell.
There has been some evidence for a functional link between Parcs/
Gpn3 and RNAP II in yeast. Conditional silencing of the Parcs/Gpn3
ortholog in yeast (YLR243W) inhibited gene expression in the same
manner as suppressing either Rpb11 or Rpb50, two individual
subunits of RNAP II [8]. We demonstrated here for the ﬁrst time
that Parcs/Gpn3 is also needed for transcriptional activity of RNA
polymerase II in mammalian cells. Our ﬁndings that the suppression
of Parcs/Gpn3 expression reduces overall transcriptional activity in
MDA-MB-468 and MCF-12A cells provide evidence that Parcs/Gpn3 is
involved in regulating transcription in both, yeast and human cells. An
involvement of Parcs/Gpn3 in a basic cellular function such as
transcription would explain the conservation of this protein through
evolution. Notably, our data clearly demonstrate that the mechanism
by which Parcs/Gpn3 is necessary for optimal transcriptional activity
is through the correct sub-cellular localization RNAP II. We have
clearly demonstrated that in the absence of Parcs/Gpn3 the Rpb1
subunit of RNAP II is in the wrong cellular compartment: the
cytoplasm. Thus, Parcs/Gpn3 joins the selected group of proteins
involved in the nuclear accumulation of RNAP II, which until our
report included only two very recently described proteins, Gpn1/
RPAP4 [26] and Iwr1 [27]. Parcs/Gpn3 may be participating directly in
the process of RNAP II nuclear import, or in the nuclear retention of
RNAP II. It is possible that Parcs/Gpn3 could theoretically participate
in RNAP II assembly, as the inhibition of this process by depleting any
subunit of RNAP II with speciﬁc siRNAs also results in a cytoplasmic
accumulation of Rpb1 [28]. Parcs/Gpn3was described as a protein that
directly binds to, and is needed for optimal activity of Apaf-1 [1]. A
role for Parcs/Gpn3 as a chaperone for Apaf-1 is the best model to
explain why this protein is important for optimal Apaf-1 function [1].
So, an attractive, but totally speculative model, would be that Parcs/
Gpn3 could function as a chaperone for RNAP II assembly in the
cytoplasm, a step apparently crucial for RNAP II nuclear import [28].
The mechanisms controlling the assembly, entry and retention of
RNAP II in the cell nucleus have ﬁnally started to be revealed. These
research topics will certainly be very active and will yield exciting
fruits in the near future.
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